Covid-19 Research

Article Figures

The Correlation between the Efficacy and Survival of Chemotherapy Combined with PD-1 and Granulocyte Colony-Stimulating Factor in Patients with Advanced NSCLC

View article figures, article metadata, topics, DOI, abstract, and related articles from the JBRES article record.

View Abstract Article Library
The Correlation between the Efficacy and Survival of Chemotherapy Combined with PD-1 and Granulocyte Colony-Stimulating Factor in Patients with Advanced NSCLC
jbres2206-g001.webp

Article Figures

Abstract

<p>Objective: This study investigates the relationship between the prophylactic use of granulocyte colony-stimulating factors and clinical efficacy, as well as survival outcomes, in patients with advanced non-small cell lung cancer who develop neutropenia following platinum-based dual-drug chemotherapy combined with immunotherapy.<br><br>Methods: A retrospective analysis was conducted on patients diagnosed with advanced non-small cell lung cancer and neutropenia in our department from 2021 to 2023. All patients received chemotherapy combined with immunotherapy. The prevention group was given long-acting granulocyte-stimulating factor for preventive treatment, while the control group did not receive preventive treatment.<br><br>Consequence: The results of univariate and multivariate analyses in this study indicate that pathological type, distant metastasis, and prophylactic use of granulocyte-stimulating factor are important influencing factors for Progression-Free Survival (PFS). After receiving chemotherapy combined with immunotherapy, the median PFS in the prevention group was 15.500 months, while that in the control group was 8.000 months (p = 0.010). This reduced the risk of disease progression by 80.3% (p = 0.039), which was statistically significant. Additionally, the median PFS for patients with adenocarcinoma components was 15.000 months, while that for patients with squamous cell carcinoma was 7.500 months (p = 0.020), which was also statistically significant. The median PFS for patients with distant metastasis was 5.000 months, while that for patients without distant metastasis was 14.500 months (p = 0.014), and the risk of disease progression increased by 6.396 times (p = 0.047).<br><br>Conclusion: Patients with adenocarcinoma components, those with distant metastasis, and those who benefit from chemotherapy combined with immunotherapy by receiving preventive use of granulocyte-stimulating factor can experience a reduced risk of disease progression. This suggests the necessity of closely monitoring neutrophil levels and taking timely intervention measures during the post-treatment monitoring period.<br></p>

Similar Topic Articles

  • Bleeding and Thrombotic Complications in Patients with Premalignant Hematologic Conditions: Diagnostic and Therapeutic Challenges
    Nowroozi M*
    Published: 2026-02-19
    Abstract PDF DOI
  • Bioactive Compounds in Anti-Inflammatory Prevention
    Joanna Soin*
    Published: 2025-09-04
    Abstract FullText HTML PDF DOI
  • Commercial Use of Moringa Capsule in Bangladesh: A Pharmacy Based Study
    Daigo Hirao, Subrina Jesmin*, Takehito Sugasawa, Matsuishi Yujiro, Abdullah Al-Mamun, Arifur Rahamn, Nobutake Shimojo and Chishimba Nathan Mowa
    Published: 2025-06-09
    Abstract FullText HTML PDF DOI
  • The Use of Nosodes with Increased Potency (Increasing the Potency of Nosodes) Leads to the Cure of Serious Diseases
    Praznikov Victor
    Published: 2025-04-30
    Abstract FullText HTML PDF DOI
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership